Singapore, Jan. 13 -- US-based Nuvation Bio Inc., a global oncology company focused on tackling some of the toughest challenges in cancer treatment, and Japan's Eisai Co., Ltd, a human-centered global leading research-based pharmaceutical company working in the neurology and oncology therapeutic areas, have announced an exclusive license and collaboration agreement that significantly expands the long-term global footprint of taletrectinib (marketed as IBTROZI(R) in the US and Japan).

Taletrectinib is a highly selective, next-generation oral treatment currently approved for patients living with advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) in the US, China and Japan.

Eisai will now have exclusive development, registra...